Delays in drug registration by the country's Medicines Control Council (MCC), contribute to depriving South African HIV patients of important fixed dose combination antiretroviral (ARV) drugs. But there are indications that the effects of the delays are being felt even farther afield. In December 2010, South Africa announced a new, two-year tender for ARVs which halved drug costs for the national HIV treatment programme; The tender however failed to include many fixed dose ARV combinations, which although approved by bodies like the World Health Organisation are not yet registered by the MCC for use in South Africa.